Executive Activity and Strategic Developments at HCW Biologics Underpin Recent Corporate Moves
Hing C. Wong, CEO of HCW Biologics Inc., engaged in significant personal transactions involving the company’s common stock and purchase warrants in May 2026. These acquisitions were coupled with several major corporate developments for HCW Biologics, including receiving a $7 million upfront license fee from Beijing Trimmune Biotech Co., Ltd., compl…